Imago BioSciences, Inc. (Imago) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced two abstracts have been accepted for oral presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 11-14, 2021.
ASH 2021 Presentation Details:
Oral Presentation Title: “A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Advanced Myelofibrosis”
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Presentation Date/Time: December 11, 2021, at 12:00 PM ET
Location: Georgia World Congress Center, A411-A412
Oral Presentation Title: “A Phase 2 Study of the LSD1 Inhibitor IMG-7289 (Bomedemstat) for the Treatment of Essential Thrombocythemia (ET)”
Session Name: Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Presentation Date/Time: Sunday, December 12, 2021, at 9:45 AM ET
Location: Georgia World Congress Center, Hall C1
Abstracts are available on the ASH meeting website at www.hematology.org.
About Imago BioSciences
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006300/en/
Imago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and Exposition $IMGO #ASH21
Contacts
Investors
Laurence Watts
Gilmartin Group, LLC.
laurence@gilmartinir.com
Media
Will Zasadny
Canale Communications
will.zasadny@canalecomm.com
